BioMarin Suffers Another Blow to Rare Disease Portfolio in Phase 3 Flop on May 20, 2026 Biological Markers BioMarin BMN Clinical Benefit Deficiency ENPP1 gene Infrequent portfolio prepulse inhibition activity regulatory risk Voxzogo hip injuries +
BioMarin's rare disease therapy shows no clinical benefit in Phase 3 test on May 19, 2026 BioMarin BMN Clinical Benefit Deficiency ENPP1 gene growth Z-score Hereditary Diseases Infrequent inorganic pyrophosphate Plasma prepulse inhibition activity Rare Diseases RGI-C scores Rickets Severities +
BioMarin Acquires Inozyme Pharma for $270M, Gaining Phase 3 Rare Disease Therapy on May 16, 2025 Acquisition BioMarin Deficiency ENPP1 gene Enzyme Replacement Therapy Infrequent Inozyme INZ-701 Pharma Phase 3 clinical trial +